The current influenza strain antigen for the 2019-2020 vaccine season produced by FSUE SPbSRIVS FMBA of Russia promptly for the WHO system (GISRS) was used by the key laboratory (NIBSC) for manufacturing the standard antigen and received catalog number 19/154. This indicates a high level of quality of SPbSRIVS products that meet not only the
Tagged under: , ,
As part of the activities organized by the BIONICA project, which is coordinated by the vaccine plant MECHNIKOV and the National Autonomous University of Nicaragua (UNAN-Managua), from October 26 to November 2, the BIONICA camp was held at the UNAN-León. In that camp, Pharmaceutical Chemistry students of both universities shared their knowledge and experiences in
September 4-5, in Moscow took place the World Health Organization Conference on preventing the restoration of malaria transmission. In a discussion of current issues of malaria elimination in the European Region participated George Ignatiev, Deputy Director for Science Programs in SPbSRIVS. The malaria situation in Russian Federation in not the topic for discussion by public,
Tagged under: , ,

SPbSRIVS took part in IVW 2017

The leading international influenza vaccines conference IVW 2017 is invariably attended by prominent influenza virologists. Mr. John Oxford (founder of influenza vaccinology in the modern sense, pictured), Mr. Peter Palese (expert on universal vaccines), Mr. Ad Osterhaus (expert on prepandemic vaccines against animal flu), Mr. John Wood (expert in biological standardization), Mr. Robert Webster (expert

SPbSRIVS supports applied research

The project “Development of an encapsulation and immobilization technology for multipotent mesenchymal stromal cells and of an inhalation targeted delivery method in the treatment for severe upper respiratory burns” by the Mendeleyev Russian Chemistry and Technology University will be given support by SPbSRIVS. The project has been submitted to the grant contest held as part
It was decided to establish a specialized department of immunobiotechnology directly at the SPbSRIVS production facility. At the meeting of the Academic Council of the St. Petersburg State Chemical and Pharmaceutical Academy (SPCPA), the establishment of the new specialized Department of Immunobiotechnology was unanimously supported by its researchers, and the agreement between the two institutions
250 thousand Nicaraguans will be vaccinated by the Russian vaccine for prevention of influenza produced SPbSRIVS FMBA of Russia. Campaign for vaccination of the elderly was launched in Managua on may 3, 2016. Recall that on 26 April 2016 we have started deliveries of the Russian vaccine for prevention of influenza in Cuba and in Nicaragua.
Tagged under: ,